Why Buccal and Sublingual Exposure Data Should Not Be Treated as Equivalent

Buccal and sublingual exposure data should not be treated as equivalent because the two delivery sites differ in epithelial thickness, permeability, salivary environment, film residence, mechanical movement, tissue surface area, and likely rate of peptide transport. An ex vivo buccal flux value, a sublingual dissolution result, or a pharmacokinetic profile obtained after one placement condition therefore cannot be transferred automatically to the other route, even when the peptide dose and film composition appear similar.

This evidence boundary is central to oromucosal peptide film research. “Oromucosal” is a useful umbrella term, but the umbrella contains distinct anatomical delivery environments. A scientifically meaningful exposure comparison must retain the exact site where the film was placed and the tissue through which transport was measured.

Research-use notice for comparisons of buccal and sublingual peptide exposure data: InStrips products are offered for research and analytical study of site-specific film release, mucosal permeation, pharmacokinetics, and related oromucosal delivery variables. Buccal or sublingual exposure measurements should not be interpreted as evidence for diagnosis, treatment, cure, prevention, correction of an absorption disorder, or any other medical or clinical outcome.

The term “exposure” itself also needs definition. Depending on the experiment, it may describe peptide concentration in a donor medium, amount retained in tissue, flux across excised mucosa, or concentration measured in plasma. These endpoints are related but not interchangeable.

Buccal and Sublingual Are Different Routes Within Oromucosal Delivery

Buccal administration places a dosage form:

• against the inner cheek

Sublingual administration places it:

• beneath the tongue

That positional difference changes the biological environment surrounding the film.

The Epithelial Barriers Are Not the Same

Buccal epithelium is commonly reported at roughly:

• 500 to 800 micrometers

while sublingual epithelium is commonly around:

• 100 to 200 micrometers

This difference alone provides a reason not to assume identical permeability.

Greater Sublingual Permeability Does Not Provide a Conversion Factor

Researchers cannot simply say:

• sublingual tissue is thinner, therefore exposure will be a fixed multiple of buccal exposure

because transport also depends on:

• peptide properties
• film release
• fluid conditions
• residence time

The Same Nominal Dose Can Produce Different Local Concentrations

A film containing the same amount of peptide may behave differently depending on placement.

Local concentration is influenced by:

• film contact area
• hydration rate
• saliva volume
• release direction
• fluid turnover

Nominal dose alone therefore does not establish equivalent tissue exposure.

Film Residence Is Different at the Two Sites

The cheek can provide a relatively stable surface for a mucoadhesive film.

The sublingual site is affected more directly by:

• tongue movement
• saliva pooling
• swallowing

A film may therefore remain in contact with tissue for different durations.

Exposure Is a Product of Both Rate and Time

A highly permeable membrane exposed briefly and a less permeable membrane exposed for an extended period represent different transport systems.

This means researchers should consider both:

• transport rate
• duration of contact

Rapid Sublingual Permeation Does Not Automatically Mean Greater Total Exposure

A peptide could cross the sublingual barrier rapidly while much of the dose is simultaneously:

• diluted
• redistributed
• swallowed

The resulting total systemic exposure must be measured.

Long Buccal Residence Does Not Automatically Mean Greater Exposure Either

A cheek film could remain attached for a long period while:

• peptide release remains slow
• epithelial permeability remains limited
• peptide undergoes degradation

Residence and absorption should therefore remain separate variables.

In-Vitro Release Data Cannot Define Route Equivalence

A dissolution test measures peptide leaving a formulation into a fluid environment.

It does not include:

• epithelial transport
• tissue metabolism
• blood flow

Two films showing identical release profiles can still produce different buccal and sublingual exposure.

Ex Vivo Permeation Is Closer to the Tissue Question

A diffusion-cell experiment measures movement across an excised membrane.

Useful variables include:

• cumulative permeated amount
• flux
• lag time
• permeability coefficient

These data are site specific.

Buccal Flux Should Not Be Relabeled as Sublingual Flux

If the experimental tissue came from the cheek, the measured value describes:

• buccal permeation under those laboratory conditions

It does not directly measure sublingual permeability.

Generic “Oral Mucosa” Labels Can Hide This Problem

Some literature uses broad terminology for tissue obtained from the mouth.

Before comparing studies, researchers should determine:

• exact anatomical region
• species
• tissue preparation

Species Can Confound Route Comparisons

Suppose a study reports:

• porcine buccal permeability

and another reports:

• rabbit sublingual permeability

The difference cannot be assigned solely to anatomical site because species also changed.

Matched Ex Vivo Studies Are Stronger

A more controlled comparison uses:

• the same species
• the same peptide
• the same formulation
• the same apparatus
• the same analytical method

while varying the tissue site.

Film Contact Area Should Be Normalized

A larger buccal film and smaller sublingual film can present different:

• total peptide load
• contact area
• concentration per square centimeter

Raw permeated amount is difficult to compare without accounting for these variables.

Flux Per Unit Area Can Improve Comparison

Normalizing transport to membrane area helps distinguish:

• larger contact area
• greater intrinsic transport rate

It still does not remove differences in tissue structure or fluid environment.

Saliva Creates a Major Site-Specific Difference

Both routes encounter oral fluid, but the sublingual space can expose formulations to substantial fluid pooling and redistribution.

Buccal films may instead be designed to resist washout through prolonged mucoadhesion.

Static Ex Vivo Systems Can Underrepresent This Difference

A Franz diffusion cell may keep the donor phase relatively stable.

The living mouth includes:

• fluid secretion
• fluid movement
• swallowing
• mechanical displacement

These factors can change route-specific exposure.

Dynamic Oral Models Can Add Useful Information

Researchers can simulate:

• salivary flow
• controlled washout
• mechanical movement

to determine whether site-specific differences persist under more realistic conditions.

Film Architecture Can Make Route Data Even Less Transferable

A buccal film may include:

• a mucoadhesive layer
• a peptide-containing layer
• a saliva-resistant backing layer

A fast-dissolving sublingual film may use an entirely different architecture.

Same Peptide Does Not Mean Same Dosage Form

If film structures differ, exposure differences could result from:

• route
• formulation
• both

A cross-study comparison must separate these variables.

Permeation Enhancers Can Be Site Dependent

An enhancer can increase transport differently across tissues with different baseline permeability.

Researchers should therefore avoid transferring:

• enhancement ratio
• effective concentration
• absolute flux

from buccal to sublingual conditions without direct testing.

Tissue Retention Can Differ Even When Receiver Flux Looks Similar

Two tissues may allow a similar amount of peptide to reach the receiver compartment while retaining different amounts within the membrane.

A complete comparison may therefore measure:

• receiver amount
• tissue-associated peptide
• residual donor material

Mass Balance Helps Explain Apparent Equivalence

If two routes produce similar measured flux but one leaves much more peptide:

• in saliva
• in the film
• inside tissue

the complete exposure pattern is not actually equivalent.

Peptide Integrity Should Also Be Matched

An assay that measures intact peptide in one study and total immunoreactive material in another can produce values that look comparable but represent different analytes.

Analytical specificity is therefore part of route comparison.

Pharmacokinetic Exposure Is a Separate Evidence Level

In humans or animals, systemic exposure can be characterized through variables such as:

• Cmax
• Tmax
• AUC
• terminal concentration-time behavior

These integrate more biological processes than an ex vivo flux experiment.

Cmax and AUC Answer Different Questions

Cmax describes a peak measured concentration.

AUC describes integrated concentration over time.

A route may produce:

• a faster peak but similar total exposure
• a lower peak but more prolonged exposure

depending on absorption kinetics.

Buccal and Sublingual Tmax Should Not Be Assumed Identical

The thinner sublingual membrane can contribute to faster absorption for some compounds.

However, actual Tmax also depends on:

• film dissolution
• peptide transport
• sampling schedule
• systemic distribution

Systemic Pharmacokinetics Do Not Reveal Exact Absorption Location Automatically

After an oral film releases peptide, some material may:

• cross local mucosa
• be swallowed

A plasma concentration alone does not identify what fraction used each pathway.

Swallowed Material Creates a Route-Attribution Problem

This is especially important when comparing rapidly dissolving films.

If a substantial fraction enters saliva before mucosal transport, systemic exposure may contain contributions that differ from the intended oromucosal route.

Swallowing Controls Can Strengthen Experimental Attribution

Specialized study designs may compare:

• normal placement
• conditions designed to modify swallowing or oral residence
• reference administration routes

depending on the research question.

Bioavailability Requires a Reference

Absolute bioavailability generally compares systemic exposure with an intravenous reference.

Relative bioavailability compares one non-intravenous formulation or route with another.

Those are different calculations.

Buccal Bioavailability Cannot Be Assigned to Sublingual Delivery

If systemic exposure was measured after cheek placement, the resulting estimate belongs to that formulation and placement condition.

It cannot automatically characterize:

• under-tongue placement

even when nominal dose is identical.

Cross-Study Comparisons Can Be Confounded by Sampling Schedules

A rapidly absorbed sublingual formulation requires sufficiently early blood sampling to capture its peak accurately.

If another study samples later, apparent Cmax differences may reflect study design partly rather than route alone.

Participant Behavior Can Influence Oromucosal Exposure

Human exposure can vary with:

• film placement
• tongue movement
• swallowing frequency
• salivary flow
• adherence to placement instructions

These variables can differ between buccal and sublingual administration.

Placement Instructions Are Therefore Part of the Experimental Method

A study should ideally describe:

• where the film was positioned
• how long it was kept there
• whether participants avoided food or drink
• how swallowing was handled

Exposure Equivalence Requires Direct Testing

To claim that two routes provide equivalent exposure, researchers would need an appropriately designed comparative study.

This may include:

• matched peptide dose
• matched formulation where feasible
• buccal administration
• sublingual administration
• serial concentration measurements
• predefined equivalence criteria

Similar Mean AUC Is Not Automatically Formal Bioequivalence

Regulatory bioequivalence generally requires predefined statistical comparison of pharmacokinetic parameters and confidence intervals.

Two descriptive means that look similar do not establish equivalence by themselves.

Interparticipant Variability Matters

Two routes can have similar average exposure while differing in:

• variance
• range
• frequency of very low or very high exposure

Route characterization should therefore include variability where possible.

Peptide-Specific Data Should Not Be Generalized Across Molecules

Even if buccal and sublingual exposure were comparable for one peptide, another peptide could behave differently because of:

• size
• charge
• hydrophobicity
• stability
• polymer interaction

Formulation-Specific Data Should Not Be Generalized Across Films Either

A change in:

• polymer
• backing layer
• permeation enhancer
• film thickness

can change exposure even at the same anatomical site.

Oral-Fluid Effects Are a Major Reason Equivalence Cannot Be Assumed

Differences in fluid exposure can alter the amount of peptide remaining at the tissue interface.

The mechanisms behind this are examined in research on saliva and oral-fluid effects on peptide film performance.

Research Notes: Exposure Data Need a Route Label and an Endpoint Label

A useful way to prevent overinterpretation is to describe every number with two labels. First, specify the site: buccal or sublingual. Second, specify what “exposure” actually means: release into fluid, tissue retention, ex vivo flux, plasma Cmax, or systemic AUC.

Without those labels, values from fundamentally different experiments can appear directly comparable. With them, it becomes clear why a buccal permeability coefficient cannot simply replace sublingual permeability data, and why ex vivo transport cannot substitute for route-specific human pharmacokinetics.

External Route-Comparison Evidence

The review Novel Liquid-Based Approaches for Transmucosal Drug Delivery distinguishes buccal and sublingual administration as separate oromucosal routes and discusses anatomical, epithelial, and delivery-environment variables that influence transmucosal exposure.

What Route-Specific Exposure Research Can Establish

Appropriately designed experiments may establish:

• buccal peptide-release profiles
• sublingual peptide-release profiles
• site-specific permeability
• site-specific tissue retention
• route-specific pharmacokinetic exposure
• direct differences between matched placement conditions

What One Route's Exposure Data Do Not Establish

Buccal data do not independently establish:

• sublingual flux
• sublingual Cmax or Tmax
• sublingual AUC

and sublingual data do not independently establish the corresponding buccal values.

Questions to Ask Before Comparing Buccal and Sublingual Data

Researchers should identify:

• Where exactly was the film placed?
• Which mucosal tissue was used?
• Was the same species studied?
• Was the formulation identical?
• Was dose normalized to film area?
• Were saliva or dynamic-flow conditions comparable?
• Was peptide integrity measured?
• Was exposure defined as release, flux, tissue retention, or plasma concentration?
• Was systemic exposure measured directly?
• Was equivalence actually tested statistically?

Final Perspective

Buccal and sublingual exposure data should not be treated as equivalent simply because both routes place a peptide film inside the mouth.

The cheek and floor of the mouth differ in epithelial thickness, permeability, fluid environment, film residence, mechanical movement, available surface area, and likely transport kinetics. Formulation architecture, analytical methods, peptide properties, and swallowing can widen those differences further.

The strongest oromucosal peptide research therefore keeps exposure site specific. Buccal results should describe buccal conditions, sublingual results should describe sublingual conditions, and claims of equivalent exposure require direct comparative evidence rather than anatomical assumption.